Current and emerging sequencing-based tools for precision cancer medicine.

Current precision cancer medicine is dependent on the analyses of a plethora of clinically relevant genomic aberrations. During the last decade, next-generation sequencing (NGS) has gradually replaced most other methods for precision cancer diagnostics, spanning from targeted tumor-informed assays and gene panel sequencing to global whole-genome and whole-transcriptome sequencing analyses. The shift has been impelled by a clinical need to assess an increasing number of genomic alterations with diagnostic, prognostic and predictive impact, including more complex biomarkers (e.g. microsatellite instability, MSI, and homologous recombination deficiency, HRD), driven by the parallel development of novel targeted therapies and enabled by the rapid reduction in sequencing costs. This review focuses on these sequencing-based methods, puts their emergence in a historic perspective, highlights their clinical utility in diagnostics and decision-making in pediatric and adult cancer, as well as raises challenges for their clinical implementation. Finally, the importance of applying sensitive tools for longitudinal monitoring of treatment response and detection of measurable residual disease, as well as future avenues in the rapidly evolving field of sequencing-based methods are discussed.
Competing Interests: Declaration of competing interest A.E has received honoraria from Amgen, AstraZeneca, Bayer, Diaceutics, and Roche. R.R. has received honoraria from AbbVie, AstraZeneca, Illumina, Janssen and Roche. T.F. is a co-founder and scientific advisor of the companies Qlucore AB, Cantargia AB, and Lead Biologics Intl, and has received honoraria from Illumina Inc.
(Copyright © 2024. Published by Elsevier Ltd.)